Recently, the CEO of Turing Pharmaceuticals garnered public attention when he chose to raise the price of one of the company's drugs, Daraprim, by 5000% overnight. An economic discussion ensued that included Hillary Clinton and many public news outlets. This debate presents complex economic considerations centered around a single question: Should the government regulate prescription drug prices?

The Adam Smith Society's Rice Chapter has organized a debate to further explore this question. We invite you to hear from:

• Vivian Ho - the Director of the Center for Health and Biosciences at the Baker Institute.
• Yevgeniy Feyman - a Fellow and Deputy Director of the Manhattan Institute's Center for Medical Progress.

Please join Adam Smith Society's Rice Chapter on December 1 at 6:00 and come prepared to learn more about government's regulation of prescription drug prices. We encourage an open dialogue on this important topic. Drinks and appetizers will be provided.